The increasingly blurry lines between Germany’s medical and recreational cannabis markets are continuing to cause conflict among lawmakers and industry
Last week, the Business of Cannabis: Berlin Executive Summit welcomed over 150 executives, policymakers, and thought leaders to take stock of how the first eight months of Germany’s landmark CanG bill had impacted the market and discuss how the uncertain future could play out.Â
While little common ground was found during Friday’s debate, the well-trodden rhetoric from each side emphasised that the implementation of CanG remains a controversial and divisive issue in Germany.Â
From October 17, the majority of doctors in Germany will be able to prescribe medical cannabis for reimbursement without securing prior approval of the health insurance companies.Â
Germany’s flourishing medical cannabis market is now forecast to top €420m this year, according to Prohibition Partners’ upcoming German Cannabis
Germany’s long-anticipated ‘Pillar 2’ is in danger of being abandoned by the government amid ongoing political roadblocks both domestically and
In July, Germany submitted a draft of its Industrial Hemp Liberalization Act, a bill that promises to do away with
Medical cannabis prescriptions have exploded across Germany since April 01 when its landmark CanG Act was brought into force. While
Chill Brands Chill Brands’ ongoing boardroom debacle took another dramatic turn this week following revelations that its ousted directors
Award-winning Frankfurt-based company Bloomwell Group GmbH (“Bloomwell Group”) today announced the launch of Germany’s largest centralised digital platform for medical
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
